AGP Executive Report
Last update: 4 hours agoCancer Research: Kraków-based Ryvu Therapeutics and Menarini reported initial Phase II activity for dapolsertib in heavily pretreated aggressive B-cell lymphoma, including patients previously treated with CAR-T therapy. Detailed results are due at the ASH meeting on Dec. 13. Clinical AI: A Polish study of 1,443 colonoscopies found precancerous growth detection fell after AI-assisted technology was introduced, though researchers could not establish that AI caused the decline. Findings underline the need to monitor clinicians’ skills as hospitals adopt diagnostic tools.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.